Stiripentol in Dravet syndrome: Results of a retrospective U.S. study. Issue 9 (12th July 2013)

• Record Type: Journal Article
• Authors: Wirrell, Elaine C.; Laux, Linda; Franz, David N.; Sullivan, Joseph; Saneto, Russell P.; Morse, Richard P.; Devinsky, Orrin; Chugani, Harry; Hernandez, Angel; Hamiwka, Lorie; Mikati, Mohamad A.; Valencia, Ignacio; Le Guern, Marie‐Emmanuelle; Chancharme, Laurent; de Menezes, Marcio Sotero
• Is Part Of: Epilepsia. Volume 54:Issue 9(2013:Sep.)
• Page Start: 1595
• Page End: 1604
• Publication Date: 2013-07-12
• Subjects: Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.12303
• Languages: English
• ISSNs: 0013-9580

Abstract

<abstract abstract-type="main" id="epi12303-abs-0001"> <title>Summary</title> <sec id="epi12303-sec-0001" sec-type="section"> <title>Purpose</title> <p>To review the efficacy and tolerability of stiripentol in the treatment of U.S. children with Dravet syndrome.</p> </sec> <sec id="epi12303-sec-0002" sec-type="section"> <title>Methods</title> <p>U.S. clinicians who had prescribed stiripentol for two or more children with Dravet syndrome between March 2005 and 2012 were contacted to request participation in this retrospective study. Data collected included overall seizure frequency, frequency of prolonged seizures, and use of rescue medications and emergency room (ER)/hospital visits in the year preceding stiripentol initiation, and with stiripentol therapy. We separately assessed efficacy in the following treatment groups: group A, stiripentol without clobazam or valproate; group B, stiripentol with clobazam but without valproate; group C, stiripentol with valproate but without clobazam; and group D, stiripentol with clobazam and valproate. In addition, adverse effects were recorded.</p> </sec> <sec id="epi12303-sec-0003" sec-type="section"> <title>Key Findings</title> <p>Thirteen of 16 clinicians contacted for study participated and provided data on 82 children. Stiripentol was initiated a median of 6.0 years after seizure onset and 1.2 years after diagnosis of Dravet syndrome. Compared to baseline, overall seizure frequency was reduced in 2/6 in group A, 28/35 in group B, 8/14 in group C, and 30/48 in group D. All children with prolonged seizure frequency greater than quarterly during the baseline period experienced a reduction in this frequency on the various treatment arms with stiripentol. Similarly, 2/4 patients in group A, 25/25 in group B, 5/10 in group C, and 26/33 in group D experienced reduction in frequency of rescue medication use and 1/1 in group A, 12/12 in group B, 3/5 in group C, and 18/19 in group D had reduction in frequency of ER/hospital visits. Adverse effects were reported in 38, most commonly sedation and reduced appetite. Four patients (5%) discontinued stiripentol for adverse effects and two (2%) for lack of efficacy.</p> </sec> <sec id="epi12303-sec-0004" sec-type="section"> <title>Significance</title> <p>Stiripentol is an effective and well‐tolerated therapy that markedly reduced frequency of prolonged seizures in Dravet syndrome.</p> </sec> </abstract>